184 related articles for article (PubMed ID: 15251938)
41. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
42. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
43. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of RASSF1A promoter methylation in operable breast cancer.
Kioulafa M; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
Clin Biochem; 2009 Jul; 42(10-11):970-5. PubMed ID: 19374895
[TBL] [Abstract][Full Text] [Related]
45. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
46. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
47. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation.
Suehiro Y; Okada T; Okada T; Anno K; Okayama N; Ueno K; Hiura M; Nakamura M; Kondo T; Oga A; Kawauchi S; Hirabayashi K; Numa F; Ito T; Saito T; Sasaki K; Hinoda Y
Clin Cancer Res; 2008 Jun; 14(11):3354-61. PubMed ID: 18519763
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.
Veeck J; Geisler C; Noetzel E; Alkaya S; Hartmann A; Knüchel R; Dahl E
Carcinogenesis; 2008 May; 29(5):991-8. PubMed ID: 18356147
[TBL] [Abstract][Full Text] [Related]
49. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer.
Ichikawa D; Koike H; Ikoma H; Ikoma D; Tani N; Otsuji E; Kitamura K; Yamagishi H
Anticancer Res; 2004; 24(4):2477-81. PubMed ID: 15330201
[TBL] [Abstract][Full Text] [Related]
50. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue.
Yan PS; Venkataramu C; Ibrahim A; Liu JC; Shen RZ; Diaz NM; Centeno B; Weber F; Leu YW; Shapiro CL; Eng C; Yeatman TJ; Huang TH
Clin Cancer Res; 2006 Nov; 12(22):6626-36. PubMed ID: 17121881
[TBL] [Abstract][Full Text] [Related]
51. DNA methylation in benign breast epithelium in relation to age and breast cancer risk.
Euhus DM; Bu D; Milchgrub S; Xie XJ; Bian A; Leitch AM; Lewis CM
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1051-9. PubMed ID: 18483325
[TBL] [Abstract][Full Text] [Related]
52. Extracellular DNA in breast cancer: Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors.
Rykova EY; Laktionov PP; Skvortsova TE; Starikov AV; Kuznetsova NP; Vlassov VV
Ann N Y Acad Sci; 2004 Jun; 1022():217-20. PubMed ID: 15251963
[TBL] [Abstract][Full Text] [Related]
53. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients.
Agostini M; Enzo MV; Bedin C; Belardinelli V; Goldin E; Del Bianco P; Maschietto E; D'Angelo E; Izzi L; Saccani A; Zavagno G; Nitti D
Cancer Biomark; 2012; 11(2-3):89-98. PubMed ID: 23011155
[TBL] [Abstract][Full Text] [Related]
54. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
55. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
56. Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk.
Euhus DM; Bu D; Ashfaq R; Xie XJ; Bian A; Leitch AM; Lewis CM
Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1812-21. PubMed ID: 17855699
[TBL] [Abstract][Full Text] [Related]
57. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.
Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164
[TBL] [Abstract][Full Text] [Related]
58. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
59. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer.
Fiegl H; Jones A; Hauser-Kronberger C; Hutarew G; Reitsamer R; Jones RL; Dowsett M; Mueller-Holzner E; Windbichler G; Daxenbichler G; Goebel G; Ensinger C; Jacobs I; Widschwendter M
Clin Cancer Res; 2008 Jun; 14(11):3494-502. PubMed ID: 18519782
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
